The quote below is from a Morningstar analyst report on Genmab. $11.3B is the highest sales estimate I've seen for Darzalex but in any case you can see that even just for Darzalex any "step down" in 2024 and 2027 from "mid-single digits" would be significant, so it's not surprising that analysts keep asking about it.
"We think Darzalex will continue to be a widely used treatment for multiple myeloma due to its notable efficacy and safety profile. By 2030, we model over $11.3 billion in Darzalex sales, which corresponds to about DKK 13 billion in royalties to Genmab."
News 
Market Data 
Discover 
